JP6603662B2 - タンパク質のチオエーテルコンジュゲーション方法 - Google Patents

タンパク質のチオエーテルコンジュゲーション方法 Download PDF

Info

Publication number
JP6603662B2
JP6603662B2 JP2016538783A JP2016538783A JP6603662B2 JP 6603662 B2 JP6603662 B2 JP 6603662B2 JP 2016538783 A JP2016538783 A JP 2016538783A JP 2016538783 A JP2016538783 A JP 2016538783A JP 6603662 B2 JP6603662 B2 JP 6603662B2
Authority
JP
Japan
Prior art keywords
protein
conjugation
mixture
concentration
growth hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016538783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501148A5 (https=
JP2017501148A (ja
Inventor
シャルロッテ・スコー・フネシェ
トーマス・ブッデ・ハンセン
エルンスト・ブロベルグ・ハンセン
Original Assignee
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノヴォ・ノルディスク・ヘルス・ケア・アーゲー filed Critical ノヴォ・ノルディスク・ヘルス・ケア・アーゲー
Publication of JP2017501148A publication Critical patent/JP2017501148A/ja
Publication of JP2017501148A5 publication Critical patent/JP2017501148A5/ja
Application granted granted Critical
Publication of JP6603662B2 publication Critical patent/JP6603662B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016538783A 2013-12-13 2014-12-15 タンパク質のチオエーテルコンジュゲーション方法 Active JP6603662B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13197150.9 2013-12-13
EP13197150 2013-12-13
PCT/EP2014/077777 WO2015086853A1 (en) 2013-12-13 2014-12-15 Method for thioether conjugation of proteins

Publications (3)

Publication Number Publication Date
JP2017501148A JP2017501148A (ja) 2017-01-12
JP2017501148A5 JP2017501148A5 (https=) 2018-01-25
JP6603662B2 true JP6603662B2 (ja) 2019-11-06

Family

ID=49765887

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016538783A Active JP6603662B2 (ja) 2013-12-13 2014-12-15 タンパク質のチオエーテルコンジュゲーション方法

Country Status (6)

Country Link
US (1) US11219690B2 (https=)
EP (1) EP3079722B1 (https=)
JP (1) JP6603662B2 (https=)
CN (1) CN106068127B (https=)
ES (1) ES2869309T3 (https=)
WO (1) WO2015086853A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102844773B1 (ko) 2015-12-23 2025-08-13 암젠 인크 위 억제 펩티드 수용체 (gipr)에 대한 결합 단백질을 glp-1 효능제와 조합하여 사용하여 대사 장애를 치료하거나 개선시키는 방법
BR112019014588A2 (pt) 2017-01-17 2020-02-18 Amgen Inc. Método de tratamento ou amenização de distúrbios metabólicos usando agonistas do receptor de glp-1 conjugados a antagonistas para receptor do peptídeo inibidor gástrico (gipr)
CN110831969B (zh) 2017-06-20 2024-06-21 安进公司 使用抑胃肽受体（gipr）结合蛋白与glp-1激动剂的组合治疗或改善代谢障碍的方法
MX2019015544A (es) 2017-06-21 2020-07-28 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de fusion de agonistas del receptor de glp-1/proteinas de union antagonistas para el receptor peptidico inhibidor gastrico (gipr).
FI3661562T3 (fi) * 2017-08-04 2024-12-09 Amgen Inc Cys-mab:ien konjugointimenetelmä

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
BR122013003013B8 (pt) * 1999-01-14 2021-07-06 Bolder Biotechnology Inc proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
IL152804A0 (en) 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
WO2004101597A2 (en) 2003-05-13 2004-11-25 Frutarom Ltd. Methods for the reduction of disulfide bonds
EP2033662B1 (en) 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
GB0513852D0 (en) 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
WO2007109475A2 (en) * 2006-03-16 2007-09-27 Bracco Imaging S.P.A. Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines
CN101809032A (zh) 2007-08-24 2010-08-18 诺沃-诺迪斯克有限公司 用于选择性修饰蛋白质的方法
CN118767117A (zh) * 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
EP2536434B1 (en) 2010-02-16 2016-04-20 Novo Nordisk A/S Purification method
EP2595661A1 (en) 2010-07-22 2013-05-29 Novo Nordisk Health Care AG Growth hormone conjugates
EP3808378A1 (en) 2011-05-27 2021-04-21 Baxalta GmbH Therapeutic proteins with increased half-life and methods of preparing same
BR112014010406A2 (pt) * 2011-11-02 2017-04-25 Genentech Inc cromatografia de sobrecarga e eluto
CN103087183A (zh) * 2013-01-17 2013-05-08 南京邮电大学 一种光激发蛋白质中二硫键还原得到自由巯基的方法

Also Published As

Publication number Publication date
EP3079722A1 (en) 2016-10-19
ES2869309T3 (es) 2021-10-25
CN106068127B (zh) 2020-06-19
WO2015086853A1 (en) 2015-06-18
CN106068127A (zh) 2016-11-02
US20160303248A1 (en) 2016-10-20
US11219690B2 (en) 2022-01-11
EP3079722B1 (en) 2021-03-24
JP2017501148A (ja) 2017-01-12

Similar Documents

Publication Publication Date Title
JP6603662B2 (ja) タンパク質のチオエーテルコンジュゲーション方法
Liu et al. Precision conjugation: An emerging tool for generating protein–polymer conjugates
Zhang et al. Chromatographic separation of hemoglobin variants using robust molecularly imprinted polymers
JP3659261B2 (ja) 組換体タンパク質の多機能性複合体への標的化ヘテロ結合
FI113272B (fi) Parannettu proteiinien laskostamismenetelmä
US11345722B2 (en) High pH protein refolding methods
MX2014010348A (es) Composiciones de conjugados de xten y métodos para realizarlas.
US11053278B2 (en) Tangential flow filtration based protein refolding methods
PT2100904E (pt) Fase sólida para utilização num método para a purificação de conjugados de albumina
Li et al. Methods for engineering therapeutic peptides
US20140037961A1 (en) System For Purifying, Producing And Storing Biomolecules
Gerling-Driessen et al. Exploiting Oligo (amido amine) backbones for the multivalent presentation of coiled-coil peptides
Rahimizadeh et al. An albumin scaffold grafted with an alpha-helical motif delivers therapeutic payloads by modular coiled-coil assembly
JP2017501148A5 (https=)
Tallec et al. Adequate reducing conditions enable conjugation of oxidized peptides to polymers by one-pot thiol click chemistry
BR112022000760B1 (pt) Composições, método para preparar um conjugado de longa duração de um polipeptídeo fisiologicamente ativo e conjugado de fármaco de longa duração
Leong et al. Dilution versus dialysis: a quantitative study of the oxidative refolding of recombinant human alpha-fetoprotein
CN112679574B (zh) 一种基于青霉胺的多肽二硫键合成方法及其应用
JP5713006B2 (ja) チオスルホナート化合物、タンパク質及び／又はペプチドの可逆的カチオン化剤並びに可溶化方法
Kjeldsen et al. Dually reactive long recombinant linkers for bioconjugations as an alternative to PEG
CN103608463A (zh) 由使具有免疫球蛋白折叠结构的蛋白和能够形成亚单元结构的蛋白融合而得到的单体蛋白组成的多聚体蛋白的制备方法
Liu et al. Enhancing Peptide Hydrophilicity of SPPS-Derived Peptides Using Fmoc Noncanonical Amino Acids: A Review
CN120659799A (zh) 用于制备白蛋白溶液的方法及其用途和相关用途
JPH1156386A (ja) 組換えｂｄｎｆの再生方法
Strainienė Studies of the refolding processes of recombinant growth hormones

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190917

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191011

R150 Certificate of patent or registration of utility model

Ref document number: 6603662

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250